. 2009;164(5-6):175-80; discussion 180-1.
[Study of the molecular mechanisms controlling activity of protein p53 in the development of new strategies in cancer therapeutics]
[Article in
French]
Affiliations
- PMID: 20666148
Item in Clipboard
[Study of the molecular mechanisms controlling activity of protein p53 in the development of new strategies in cancer therapeutics]
[Article in
French]
Bull Mem Acad R Med Belg.
2009.
Abstract
P53 is 30. Even if the tumor suppressor functions of p53 have long been recognized, the cancer-killing activity of p53 has not yet been exploited selectively and efficiently in the clinic. Recent genetic studies in mice identified MDM2 and MDMX as key regulators of p53 and as such as specific chemotherapeutic targets for treatment of cancer. Specific MDM2 and MDMX antagonists are now being developed as tools to unleash p53 activity in various tumors.
Similar articles
-
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?Mol Cancer Res. 2009 Jan;7(1):1-11. doi: 10.1158/1541-7786.MCR-08-0423. Mol Cancer Res. 2009. PMID: 19147532 Free PMC article. Review.
-
Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.FEBS Lett. 2009 Sep 3;583(17):2710-4. doi: 10.1016/j.febslet.2009.07.021. Epub 2009 Jul 18. FEBS Lett. 2009. PMID: 19619542
-
Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.Diagn Pathol. 2014 Mar 25;9:71. doi: 10.1186/1746-1596-9-71. Diagn Pathol. 2014. PMID: 24667108 Free PMC article.
-
Expression of p14ARF overcomes tumor resistance to p53.Cancer Res. 2002 Mar 1;62(5):1305-10. Cancer Res. 2002. PMID: 11888896
-
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.Nat Rev Cancer. 2003 Feb;3(2):102-9. doi: 10.1038/nrc991. Nat Rev Cancer. 2003. PMID: 12563309 Review.
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous